It also takes part in the genesis of ccRCC by targeting Forkhead Box O3 (FOXO3a), a member of the RAS/MAPK signaling pathway, therefore becoming a potential target for ccRCC therapy [21]. The gene discussed is FOXO3; the disease is nonpapillary renal cell carcinoma.